SCHEMBL22553735

SCHEMBL22553735

C[C@@H](O)c1cnc2c(c1)c(-c1cncc(-c3ccc(N4CCCC4=O)cc3)c1)cn2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.41
BRDT Q58F21 1/20 0.41
SYK P43405 4/20 0.39
PIP4K2A P48426 1/20 0.38
NPC1 O15118 1/20 0.37
CCNC P24863 2/20 0.37
CDK8 P49336 2/20 0.37
CYP11B2 P19099 3/20 0.36
PHGDH O43175 1/20 0.36
CCR6 P51684 1/20 0.36
CD38 P28907 1/20 0.36
CYP11B1 P15538 1/20 0.36
KIT P10721 1/20 0.35
CHEK1 O14757 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
IP6K1 Q92551 1/20 0.35
IP6K3 Q96PC2 1/20 0.35
IP6K2 Q9UHH9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22553804 1.00 BRD4 (0.41) BRD4BRDTSYKPIP4K2ANPC1
SCHEMBL22553736 1.00 BRD4 (0.41) BRD4BRDTSYKPIP4K2ANPC1
SCHEMBL22553774 0.91 BRD4 (0.41) BRD4BRDTSYKPIP4K2ANPC1
SCHEMBL22553773 0.91 BRD4 (0.41) BRD4BRDTSYKPIP4K2ANPC1
SCHEMBL22554289 0.91 BRD4 (0.41) BRD4BRDTSYKPIP4K2ANPC1
SCHEMBL22554063 0.88 BRD4 (0.45) BRD4BRDTSYKPIP4K2ANPC1
SCHEMBL22553918 0.88 SYK (0.39) BRD4BRDTSYKPIP4K2ANPC1
SCHEMBL22553825 0.88 SYK (0.39) BRD4BRDTSYKPIP4K2ANPC1
SCHEMBL22553826 0.88 SYK (0.39) BRD4BRDTSYKPIP4K2ANPC1
SCHEMBL22554116 0.88 BRD4 (0.39) BRD4BRDTSYKPIP4K2ACCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 US claimed
EP-3728230-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 EP claimed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US claimed
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 US disclosed
EP-3728230-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 EP disclosed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US disclosed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS PIP5K1A, PIP5K1B, PIP5K1C BRD4 309/4885BRDT 786/4885SYK 984/4885
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1A, PIP5K1B, PIP5K1C BRD4 309/4885BRDT 786/4885SYK 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.